Newsroom

March 3, 2022
Public Notice

(Yellowknife, March 3, 2022) – Due reduced staffing capacity caused by vacancies, in-school Speech-Language Pathology (SLP) services will remain suspended through the rest of the 2022 school year.

March 1, 2022
Public Notice

(Yellowknife, March, 1, 2022) – Starting April 1st, 2022 the Northwest Territories Health and Social Services Authority will be the operator of the sobering centre located on 50th street in Yellowknife.

February 22, 2022
News Release

YELLOWKNIFE (February 22, 2022) – The Northwest Territories Health and Social Services Authority will resume labour and delivery services at Stanton Territorial Hospital for all NWT residents.

February 9, 2022
Public Notice

(Yellowknife, February 9, 2021) – The following updates to vaccination recommendations have been provided by National Advisory Committee on Immunization (NACI):

February 7, 2022
Public Notice

February 7, 2022 - Due to staffing capacities, the following service changes are in effect:

February 7, 2022
Public Notice

(Yellowknife, February 7, 2022) – Anyone who downloaded an Electronic Proof of Vaccination Credential (PVC) between January 27, 2022 at 12:00 noon and February 3, 2022 at 1:00 p.m. is being asked to redownload a new credential, to ensure that their credential can be scanned.

January 28, 2022
Public Notice

(Yellowknife, January 28, 2022) – Electronic proof of Vaccination Credentials (PVCs) are now available to children aged 5-11.

January 27, 2022
Public Notice

The National Advisory Committee on Immunization (NACI) has recommended that patients with moderate to severe immunocompromise due to disease or treatment be offered an additional fourth dose at least 6 months following their third dose.

January 26, 2022
News Release

YELLOWKNIFE (January 26, 2022) – The Northwest Territories Health and Social Services Authority will begin a phased resumption of labour  and delivery services at Stanton Territorial Hospital.

January 19, 2022
Public Notice

With the announcement by the Government of Canada approving the use of Pfizer’s Paxlovid COVID-19 antiviral drug there is now one

Pages